Actinic keratoses:
Indications for: ZYCLARA
Actinic keratoses on face and balding scalp in immunocompetent patients.
Adult Dosage:
≥18yrs: Apply thin film to affected area (face or balding scalp) and rub in once daily at bedtime; leave on for 8 hours, wash off with mild soap and water. Treat for two 2-week cycles separated by a 2-week no-treatment cycle. Max two packets per application and one treatment course per area. Apply to intact skin only; Interrupt if severe reaction occurs; do not extend treatment cycle due to missed doses or rest periods. Wash hands before/after application.
Children Dosage:
<18yrs: not recommended.
ZYCLARA Warnings/Precautions:
Immunosuppressed. Autoimmune conditions. Not for treating urethral, intra-vaginal, cervical, rectal or intra-anal human papilloma viral disease, xeroderma pigmentosum, superficial basal cell carcinoma. Sun sensitivity. Avoid eyes, lips, nose, mouth, mucous membranes, sun or UV light (use sunscreen daily). Do not occlude. Pregnancy (Cat.C). Nursing mothers.
ZYCLARA Classification:
Immune response modifier.
ZYCLARA Interactions:
Avoid concomitant other forms of imiquimod.
Adverse Reactions:
Local inflammation (eg, erythema, crusting, erosion, weeping, edema), pruritus, flaking, scaling, dryness, flu-like symptoms (eg, headache, fatigue, nausea, fever, chills, myalgia), transient increase in lesion counts; exacerbation of skin inflammatory conditions (eg, graft vs. host disease), chest pain, lymphadenopathy, hypo- or hyperpigmentation.
How Supplied:
Single-use packets—28
Warts:
Indications for: ZYCLARA
External genital warts. Perianal warts.
Adult Dosage:
Apply thin layer to warts and rub in once daily prior to bedtime; leave on for 8 hours. Wash off with mild soap and water. Continue until total clearance or for up to 8 weeks. Max one packet per application to treatment area. Interrupt if local skin reaction occurs; resume after several days or once the reaction subsides. Wash hands before/after application.
Children Dosage:
Not recommended.
ZYCLARA Warnings/Precautions:
Immunosuppressed. Autoimmune conditions. Not for treating urethral, intra-vaginal, cervical, rectal or intra-anal human papilloma viral disease, xeroderma pigmentosum, superficial basal cell carcinoma. Sun sensitivity. Avoid eyes, lips, nose, mouth, mucous membranes, sun or UV light (use sunscreen daily). Do not occlude. Pregnancy (Cat.C). Nursing mothers.
ZYCLARA Classification:
Immune response modifier.
ZYCLARA Interactions:
Avoid concomitant other forms of imiquimod.
Adverse Reactions:
Local inflammation (eg, erythema, crusting, erosion, weeping, edema), pruritus, flaking, scaling, dryness, flu-like symptoms (eg, headache, fatigue, nausea, fever, chills, myalgia), transient increase in lesion counts; exacerbation of skin inflammatory conditions (eg, graft vs. host disease), chest pain, lymphadenopathy, hypo- or hyperpigmentation.
How Supplied:
Single-use packets—28
